RXRX logo

RXRX
Recursion Pharmaceuticals Inc

14,626
Mkt Cap
$1.91B
Volume
14.61M
52W High
$7.89
52W Low
$2.98
PE Ratio
-2.47
RXRX Fundamentals
Price
$3.67
Prev Close
$3.77
Open
$3.65
50D MA
$4.20
Beta
2.67
Avg. Volume
20.64M
EPS (Annual)
-$1.44
P/B
1.71
Rev/Employee
$124,468.33
$1,160.13
Loading...
Loading...
News
all
press releases
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Recursion Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down
PCRX misses Q4 earnings and revenue estimates as expenses surge and shares slide, despite Exparel growth and a new 2026 outlook.
Zacks·2d ago
News Placeholder
Xenon Q4 Loss Wider Than Expected, Pipeline Development in Focus
XENE posts wider Q4 loss as R&D jumps 47%, but late-stage azetukalner studies and a $586M cash runway keep its pipeline in focus.
Zacks·2d ago
News Placeholder
Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX tops Q4 estimates as Firdapse and Agamree sales jump, lifting 2025 results and driving upbeat 2026 revenue guidance.
Zacks·3d ago
News Placeholder
ACAD Q4 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth
Acadia beats Q4 EPS estimates as Nuplazid and Daybue lift revenues 9%, but sales miss and EU setback cloud trofinetide outlook with 2026 sales at $1.22-$1.28 billion.
Zacks·3d ago
News Placeholder
Recursion Pharmaceuticals' (RXRX) Buy Rating Reaffirmed at Needham & Company LLC
Needham & Company LLC restated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday...
MarketBeat·3d ago
News Placeholder
Recursion Pharmaceuticals Q4 Earnings Call Highlights
Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection point for the company, highlighting a first positive clinical...
MarketBeat·4d ago
News Placeholder
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of +24.11% and +39.36%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Announces Earnings Results
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of...
MarketBeat·4d ago
News Placeholder
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up Following Better-Than-Expected Earnings
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up After Earnings Beat...
MarketBeat·4d ago
<
1
2
...
>

Latest RXRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.